Organon & Co(OGN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | 17.46 | EPS (ttm) | 0.78 | Insider Own | 0.64% | Shs Outstand | 262.6M | Perf Week | -1.02% |
| Market Cap | 3.58B | Forward P/E | 3.75 | EPS next Y | 8.36% | Insider Trans | 0.7% | Shs Float | 260.9M | Perf Month | -0.15% |
| Enterprise Value | 11.00B | PEG | 1.22 | EPS next Q | 0.88 | Inst Own | 83.44% | Short Float | 5.8% | Perf Quarter | 1.87% |
| Income | 0.21B | P/S | 0.58 | EPS this Y | -8.47% | Inst Trans | 0.06% | Short Ratio | 5.41 | Perf Half Y | 112.97% |
| Sales | 6.13B | P/B | 3.56 | EPS next 5Y | 3.09% | ROA | 1.57% | Short Interest | 15.14M | Perf YTD | 90.1% |
| Book/sh | 3.83 | P/C | 3.16 | EPS past 3/5Y | -41.56% -39.04% | ROE | 24.04% | 52W High | -1.12% ($13.78) | Perf Year | 32.85% |
| Cash/sh | 4.31 | P/FCF | 6.31 | Sales past 3/5Y | 0.23% -1% | ROIC | 2.2% | 52W Low | 139.54% ($5.69) | Perf 3Y | -29.34% |
| Dividend Est. | $0.08 (0.59%) | EV/EBITDA | 7.16 | EPS Y/Y TTM | -70.52% | Gross Margin | 53.09% | Volatility(W/M) | 0.39% 0.29% | Perf 5Y | -59.77% |
| Dividend TTM | 0.08 | EV/Sales | 1.8 | Sales Y/Y TTM | -2.45% | Oper. Margin | 19.41% | ATR (14) | 0.04 | Perf 10Y | - |
| Dividend Ex-Date | 2026/8/14 | Quick Ratio | 1.44 | EPS Q/Q | -28.36% | Profit Margin | 3.41% | RSI (14) | 39.36 | Recom | 3 |
| Dividend Gr. 3/5Y | -32.79% - | Current Ratio | 1.95 | Sales Q/Q | -2.26% | SMA20 | -0.77% ($13.74) | Beta | 1.54 | Target Price | $14 |
| Payout | 47.41% | Debt/Eq | 8.5 | Earnings | 2026/08/11 | SMA50 | 0.09% ($13.62) | Rel Volume | 0.74 | Prev Close | $13.67 |
| Employees | 10000 | LT Debt/Eq | 8.43 | EPS/Sales Surpr. | -6.59% - | SMA200 | 31.34% ($10.38) | Avg Volume(3M) | 2.80M | Price | $13.63 |
| IPO | 2021/5/14 | Option/Short | Yes/Yes | Trades | 7953 | Volume | 2,082,174 | Change | -0.29% |
Company
OGN is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
A global pharmaceutical company that sells women's health products, biosimilars, and established medications. It supplies women's health drugs, biosimilars, and a diverse portfolio of established brand-name pharmaceuticals to global markets, and is characterized by strong cash flow and dividends. It is a pharmaceutical company specializing in women's health.
Over the past 1 year, on the higher side
1% below its 1-year high.
OGN has weak earning power
Review management risk carefully before investing
Tap to view numbers
Growth is moderate
Earnings are expected to grow by -8.5% this year.
Tap to view numbers
The price looks about right
Trading at 17.5 times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Would have changed by -29.3% if bought 5 years ago.
Tap to view numbers
The dividend is on the small side
Pays 0.59% annually in dividends.
Tap to view numbers
Ownership looks stable
Institutions hold 83.4%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
FXH 0.04%
PILL 0.03%
PIO 0.02%
MRGR 0.02%
ARB 0.02%It ranks #4 in the industry
Based on market cap of $4B.
OGN $4B PER 17.5
LLY $1.1T PER 38.2
JNJ $642B PER 30.9
ABBV $451B PER 72.1
FAQ
What kind of company is OGN?
OGN belongs to the Healthcare sector and operates in the Drug Manufacturers - General industry.
What is the market cap of OGN?
The market cap of OGN is approximately $3.6B, ranking 1,632 within its sector.
Does OGN pay dividends?
OGN has a dividend yield of approximately 0.59%, with an annual dividend of $0.08.
What is the P/E ratio of OGN?
OGN has a P/E ratio of approximately 17.5x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for OGN?
OGN has recorded a 52-week high of $13.78 and a low of $5.69.
